• Daniel G Rayner, Dario M Ferri, Gordon H Guyatt, Paul M O'Byrne, Romina Brignardello-Petersen, Farid Foroutan, Bradley Chipps, Kaharu Sumino, Tamara T Perry, Sharmilee Nyenhuis, John Oppenheimer, Elliot Israel, Flavia Hoyte, Katherine Rivera-Spoljaric, Ellen McCabe, Susana Rangel, Lindsay E Shade, Valerie G Press, Lisa Hall, Dia Sue-Wah-Sing, Angel Melendez, Hilarry Orr, Tonya Winders, Donna D Gardner, Kathyrn Przywara, Matthew A Rank, Leonard B Bacharier, Giselle Mosnaim, and Derek K Chu.
• Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
• JAMA. 2024 Oct 28.

ImportanceThe optimal inhaled reliever therapy for asthma remains unclear.ObjectiveTo compare short-acting β agonists (SABA) alone with SABA combined with inhaled corticosteroids (ICS) and with the fast-onset, long-acting β agonist formoterol combined with ICS for asthma.Data SourcesThe MEDLINE, Embase, and CENTRAL databases were searched from January 1, 2020, to September 27, 2024, without language restrictions.Study SelectionPairs of reviewers independently selected randomized clinical trials evaluating (1) SABA alone, (2) ICS with formoterol, and (3) ICS with SABA (combined or separate inhalers).Data Extraction And SynthesisTwo reviewers independently extracted data and assessed risk of bias. Random-effects meta-analyses synthesized outcomes. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the certainty of evidence.Main Outcomes And MeasuresAsthma symptom control (5-item Asthma Control Questionnaire; range, 0-6, lower scores indicate better asthma control; minimum important difference [MID], 0.5 points), asthma-related quality of life (Asthma Quality of Life Questionnaire; range, 1-7, higher scores indicate better quality of life; MID, 0.5 points), risk of severe exacerbations, and risk of serious adverse events.ResultsA total of 27 randomized clinical trials (N = 50 496 adult and pediatric patients; mean age, 41.0 years; 20 288 male [40%]) were included. Compared with SABA alone, both ICS-containing relievers were associated with fewer severe exacerbations (ICS-formoterol risk ratio [RR], 0.65 [95% CI, 0.60-0.72]; risk difference [RD], -10.3% [95% CI, -11.8% to -8.3%]; ICS-SABA RR, 0.84 [95% CI, 0.73-0.95]; RD, -4.7% [95% CI, -8.0% to -1.5%]) with high certainty. Compared with SABA alone, both ICS-containing relievers were associated with improved asthma control (ICS-formoterol RR improvement [MID] in total score, 1.07 [95% CI, 1.04-1.10]; RD, 4.1% [95% CI, 2.3%-5.9%]; ICS-SABA RR, 1.09 [95% CI, 1.03-1.15]; RD, 5.4% [95% CI, 1.8%-8.5%]) with high certainty. In an indirect comparison with ICS-SABA, ICS-formoterol was associated with fewer severe exacerbations (RR, 0.78 [95% CI, 0.66-0.92]; RD, -5.5% [95% CI, -8.4% to -2.0%]) with moderate certainty. Compared with SABA alone, ICS-formoterol (RD, -0.6% [95% CI, -1.3% to 0%]) was not associated with increased risk of serious adverse events (high certainty) and ICS-SABA (RD, 0% [95% CI, -1.1% to 1.2%]) was not associated with increased risk of serious adverse events (moderate certainty).Conclusions And RelevanceIn this network meta-analysis of patients with asthma, ICS combined with formoterol and ICS combined with SABA were each associated with reduced asthma exacerbations and improved asthma control compared with SABA alone.

5 keywords...

hide…